Amgen regulatory update

In a four-year Phase III U.S. trial in 120 patients, Neupogen reduced the incidence of infections by 60 percent (p<0.001) and reduced the incidence of required antibiotic use by 59 percent (p<0.001).

Because the natural history of SCN isn’t well understood, AMGN has created an international registry to collect information on the disease and will provide Neupogen to patients who participate. ...